Nothing Special   »   [go: up one dir, main page]

ES2545607T3 - Antígenos de la gripe recombinantes solubles - Google Patents

Antígenos de la gripe recombinantes solubles Download PDF

Info

Publication number
ES2545607T3
ES2545607T3 ES09793751.0T ES09793751T ES2545607T3 ES 2545607 T3 ES2545607 T3 ES 2545607T3 ES 09793751 T ES09793751 T ES 09793751T ES 2545607 T3 ES2545607 T3 ES 2545607T3
Authority
ES
Spain
Prior art keywords
hemagglutinin
domain
soluble recombinant
rha
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09793751.0T
Other languages
English (en)
Inventor
Manon Couture
Nathalie Landry
Louis-Philippe Vezina
Michèle DARGIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicago Inc
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Application granted granted Critical
Publication of ES2545607T3 publication Critical patent/ES2545607T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una hemaglutinina recombinante (rHA), que comprende: a) un dominio de hemaglutinina seleccionado del grupo que consiste de los subtipos de hemaglutinina H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, y H16; y b) un dominio de oligomerización seleccionado del grupo que consiste en un péptido GCN4-pII y un dominio rico en prolina (PRD) de g-zeína de maíz, en donde los residuos de aminoácidos se adicionan al extremo del terminal C del dominio de oligomerización de tal manera que el dominio de oligomerización no termina en una hélice α; c) péptido señal d) una señal de retención en el retículo endoplásmico (ER), y en donde la rHA se produce como un homotrímero soluble quimérico.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13

Claims (1)

  1. imagen1
ES09793751.0T 2008-07-08 2009-07-07 Antígenos de la gripe recombinantes solubles Active ES2545607T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7896308P 2008-07-08 2008-07-08
US78963P 2008-07-08
PCT/CA2009/000941 WO2010003235A1 (en) 2008-07-08 2009-07-07 Soluble recombinant influenza antigens

Publications (1)

Publication Number Publication Date
ES2545607T3 true ES2545607T3 (es) 2015-09-14

Family

ID=41506627

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09793751.0T Active ES2545607T3 (es) 2008-07-08 2009-07-07 Antígenos de la gripe recombinantes solubles

Country Status (11)

Country Link
US (1) US8771703B2 (es)
EP (1) EP2294202B1 (es)
JP (1) JP5809054B2 (es)
CN (2) CN102089432A (es)
AU (1) AU2009267769B2 (es)
CA (1) CA2730171C (es)
DK (1) DK2294202T3 (es)
ES (1) ES2545607T3 (es)
HK (1) HK1154041A1 (es)
PT (1) PT2294202E (es)
WO (1) WO2010003235A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CN101978066A (zh) 2007-11-27 2011-02-16 麦迪卡格公司 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp)
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
HUE039100T2 (hu) 2009-06-24 2018-12-28 Medicago Inc Hemagglutinint tartalmazó kimer influenzavírus-jellegû részecskék
HRP20220478T1 (hr) 2009-09-22 2022-05-27 Medicago Inc. Način pripreme proteina od biljaka
AU2011217903B2 (en) 2010-02-18 2017-03-02 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
KR102143105B1 (ko) 2010-07-23 2020-08-11 이스코노바 에이비 인플루엔자 백신
MX2013003451A (es) * 2010-09-30 2013-09-02 Franvax S R L Generacion de particulas de virosoma.
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
US9597390B2 (en) * 2011-03-02 2017-03-21 Utrech University Infectious bronchitis virus (IBV) spike protein as subunit vaccine
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
CN108164602A (zh) 2011-09-20 2018-06-15 西奈山医学院 流感病毒疫苗及其应用
RU2682752C2 (ru) 2011-09-30 2019-03-21 Медикаго Инк. Повышение выхода вирусоподобных частиц в растениях
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
CN105263516A (zh) 2012-12-18 2016-01-20 西奈山伊坎医学院 流感病毒疫苗及其用途
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105247059B (zh) 2013-03-28 2021-07-06 莫迪卡戈公司 植物中流感样病毒颗粒的产生
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
TW201731865A (zh) * 2016-03-15 2017-09-16 國立清華大學 重組h7血凝素及其應用
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
BR112020025250A2 (pt) * 2018-06-12 2021-03-09 Kentucky Bioprocessing, Inc. Purificação e conjugação de vírus e antígeno
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
WO2020000100A1 (en) 2018-06-27 2020-01-02 Medicago Inc. Influenza virus hemagglutinin mutants
KR102647829B1 (ko) * 2020-04-22 2024-03-14 포항공과대학교 산학협력단 삼량체를 형성하는 코로나-19 바이러스 (COVID-19, Coronavirus Disease 2019)의 재조합 스파이크 단백질 및 식물에서의 상기 재조합 스파이크 단백질의 대량 생산 방법과 이를 기반으로하는 백신조성물 제조 방법
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof
CN111662390A (zh) * 2020-06-17 2020-09-15 天康生物(上海)有限公司 禽流感HA-Fd融合蛋白及其制备方法和疫苗
CN114773487B (zh) * 2022-05-31 2024-07-02 湖南大学 一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203177A4 (en) 1984-11-29 1987-04-28 Scripps Clinic Res POLYPEPTIDES AND ANTIBODIES AGAINST DEGGLYCOSILIZED VIRAL GLYCOPROTEINS.
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
DE69213804T2 (de) * 1991-03-28 1997-03-27 Rooperol Na Nv Zusammensetzungen von Phytosterolen mit Phytosterolinen als Immunmodulatoren
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
EP1012280B1 (en) 1997-06-11 2004-11-10 Borean Pharma A/S Trimerising module
US20010006950A1 (en) * 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6489537B1 (en) * 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
ATE342994T1 (de) 1998-08-11 2006-11-15 Biosource Tech Inc Verfahren zur gewinnung von proteinen aus der interstitiellen flüssigkeit von pflanzen
US6392121B1 (en) * 1998-10-07 2002-05-21 Boyce Thompson Institute For Plant Research Gemini virus vectors for gene expression in plants
FR2791358B1 (fr) 1999-03-22 2003-05-16 Meristem Therapeutics Promoteurs chimeriques d'expression, cassettes d'expression, plasmides, vecteurs, plantes et semences transgeniques les contenant et leurs methodes d'obtention
US7125978B1 (en) * 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60232577D1 (de) * 2001-01-18 2009-07-23 Vlaams Interuniv Inst Biotech Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
ES2563402T3 (es) * 2002-02-13 2016-03-15 Wisconsin Alumni Research Foundation Señal para el empaquetamiento de vectores del virus de la gripe
US7041500B2 (en) 2002-02-14 2006-05-09 Novavax, Inc. Insect cell line
CA2819867A1 (en) * 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants
WO2007095318A2 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
ES2224792B1 (es) * 2002-06-28 2007-02-16 Era Plantech, S.L. Produccion de peptidos y proteinas por acumulacion de cuerpos proteicos derivados de reticulos endoplasmico en plantas.
WO2004098533A2 (en) 2003-05-05 2004-11-18 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
EP1635772A4 (en) 2003-05-05 2008-02-13 Dow Agrosciences Llc STERILE IMMUNOPROPHYLACTIC AND THERAPEUTIC COMPOSITIONS DERIVED FROM TRANSGENIC VEGETABLE CELLS AND METHODS OF PRODUCTION THEREOF
CA2529647C (en) * 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CN101166827B (zh) 2005-04-29 2013-09-04 开普敦大学 在植物中表达蛋白质
JP2009502789A (ja) 2005-07-19 2009-01-29 ダウ グローバル テクノロジーズ インコーポレイティド 組み換えインフルエンザワクチン
EP1945250A4 (en) * 2005-08-16 2010-05-19 Hawaii Biotech Inc RECOMBINANT SUBUNIT VACCINE FOR INFLUENZA VIRUS
DK1937301T3 (en) 2005-10-18 2015-07-20 Novavax Inc FUNCTIONAL INFLUENZA-like particles (VLPs)
WO2008060669A2 (en) 2006-04-21 2008-05-22 Dow Agrosciences Llc Vaccine for avian influenza and methods of use
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
CA2657849A1 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US20070286873A1 (en) * 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
BRPI0812538B1 (pt) 2007-06-15 2021-03-16 Medicago Inc. processo para a síntese de uma proteína de interesse com fucosilação e xilosilação reduzidas, ácido nucleico, e proteína híbrida gnt1-galt
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CN101820903A (zh) * 2007-08-20 2010-09-01 美国弗劳恩霍夫股份有限公司 预防性和治疗性流感疫苗、抗原、组合物和方法
CN101978066A (zh) * 2007-11-27 2011-02-16 麦迪卡格公司 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp)
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
KR101956910B1 (ko) 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
DE102008009491B4 (de) 2008-02-15 2010-02-04 Rainer Brenner Vorrichtung zur Sicherung von Waren
CA2730668C (en) 2008-07-18 2020-04-28 Medicago Inc. New influenza virus immunizing epitope
WO2010025285A1 (en) 2008-08-27 2010-03-04 Arizona Board Of Regents For And On Behalf Of Arizona State University A dna replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants
WO2010077712A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
HUE039100T2 (hu) * 2009-06-24 2018-12-28 Medicago Inc Hemagglutinint tartalmazó kimer influenzavírus-jellegû részecskék

Also Published As

Publication number Publication date
CA2730171C (en) 2016-10-11
US20110104753A1 (en) 2011-05-05
PT2294202E (pt) 2015-10-09
WO2010003235A1 (en) 2010-01-14
CN105753948A (zh) 2016-07-13
AU2009267769A1 (en) 2010-01-14
DK2294202T3 (en) 2015-08-31
AU2009267769B2 (en) 2015-07-16
EP2294202B1 (en) 2015-05-20
JP2011527181A (ja) 2011-10-27
JP5809054B2 (ja) 2015-11-10
EP2294202A1 (en) 2011-03-16
CA2730171A1 (en) 2010-01-14
HK1154041A1 (en) 2012-04-13
US8771703B2 (en) 2014-07-08
CN102089432A (zh) 2011-06-08
EP2294202A4 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
ES2545607T3 (es) Antígenos de la gripe recombinantes solubles
ES2528347T3 (es) Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido n-terminal
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
ES2564281T3 (es) Formulación de anticuerpos Abeta
AR064220A1 (es) Formulacion liofilizada mab abeta
EA201290370A1 (ru) Антитела против flt3 и способы их применения
JP2014224126A5 (es)
BRPI0923346A2 (pt) Proteinas em super-helice antiparalela de cadeia simples
JP2015017245A5 (es)
CO6251291A2 (es) Anticuerpos humanizados contra el globulomero ab (20-42) y sus usos
CU20120137A7 (es) Hidrato del hidrocloruro de agomelatina y preparación de éste
AR080904A2 (es) Coagonistas del receptor de glucagon /glp - 1
CL2012003723A1 (es) Compuestos derivados de acido 2-quinolinil-acetico; composicion farmaceutica; y uso en el tratamiento del vih y sida.
ECSP12011577A (es) Produccion recombinante de péptidos
CL2011001281A1 (es) Compuestos derivados de n-acilsulfonamida, inhibidores bcl; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
ES2530457T3 (es) Secuencias peptídicas, su forma ramificada y uso de estas para aplicaciones antimicrobianas
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
ES2672497T3 (es) Procedimiento para preparar catalizadores de cianuro metálico doble altamente activos y su uso en la síntesis de polioles de poliéter
MX2013012793A (es) Aminoacidos radiomarcados para imagen de diagnostico.
WO2013098802A3 (en) Solid phase peptide synthesis via side chain attachment of hydroxyl amino acids
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
GB201019331D0 (en) Methods for the diagnosis and treatment of cancer based on AVL9
CL2009001342A1 (es) Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c; preparados farmaceuticos que lo contienen; compuesto 11 alfa-hidroxi-15 beta, 16 beta-metilen-androst-4-en-3,17-diona; procedimiento para preparar dicho compuesto que comprende el uso de microorganismos.